Cancer and Leukemia Group B Pathology Committee Guidelines for Tissue Microarray Construction Representing Multicenter Prospective Clinical Trial Tissues | Zendy

David L. Rimm | Zendy; Torsten O. Nielsen | Zendy; Scott D. Jewell | Zendy; Daniel C. Rohrer | Zendy; Gloria Broadwater | Zendy; Frederic M. Waldman | Zendy; Kisha A. Mitchell | Zendy; Baljit Singh | Zendy; Gregory J. Tsongalis | Zendy; Wendy L. Frankel | Zendy; Anthony M. Magliocco | Zendy; Jonathan F. Lara | Zendy; Eric D. Hsi | Zendy; Ira J. Bleiweiss | Zendy; Sunil Badve | Zendy; Beiyun Chen | Zendy; Peter M. Ravdin | Zendy; Richard L. Schilsky | Zendy; Ann D. Thor | Zendy; Donald A. Berry | Zendy

Open Access

Cancer and Leukemia Group B Pathology Committee Guidelines for Tissue Microarray Construction Representing Multicenter Prospective Clinical Trial Tissues

Author(s) -

David L. Rimm,

Torsten O. Nielsen,

Scott D. Jewell,

Daniel C. Rohrer,

Gloria Broadwater,

Frederic M. Waldman,

Kisha A. Mitchell,

Baljit Singh,

Gregory J. Tsongalis,

Wendy L. Frankel,

Anthony M. Magliocco,

Jonathan F. Lara,

Eric D. Hsi,

Ira J. Bleiweiss,

Sunil Badve,

Beiyun Chen,

Peter M. Ravdin,

Richard L. Schilsky,

Ann D. Thor,

Donald A. Berry

Publication year - 2011

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2010.33.2023

Subject(s) - medicine , tissue microarray , clinical trial , cancer , population , biomarker , oncology , tissue bank , pathology , companion diagnostic , molecular pathology , medical physics , biochemistry , chemistry , environmental health , gene

Practice-changing evidence requires confirmation, preferably in multi-institutional clinical trials. The collection of tissue within such trials has enabled biomarker studies and evaluation of companion diagnostic tests. Tissue microarrays (TMAs) have become a standard approach in many cooperative oncology groups. A principal goal is to maximize the number of assays with this precious tissue. However, production strategies for these arrays have not been standardized, possibly decreasing the value of the study. In this article, members of the Cancer and Leukemia Group B Pathology Committee relay our experiences as array facility directors and propose guidelines regarding the production of high-quality TMAs for cooperative group studies. We also discuss statistical issues arising from having a proportion of patients available for TMAs and the possibility that patients with TMAs fail to represent the greater study population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research